Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1966 1
1968 2
1969 1
1970 3
1971 10
1972 12
1973 6
1974 14
1975 17
1976 9
1977 14
1978 21
1979 19
1980 17
1981 21
1982 26
1983 29
1984 44
1985 47
1986 55
1987 44
1988 53
1989 57
1990 53
1991 42
1992 41
1993 33
1994 19
1995 30
1996 38
1997 26
1998 31
1999 43
2000 25
2001 36
2002 37
2003 24
2004 29
2005 44
2006 51
2007 59
2008 58
2009 74
2010 71
2011 80
2012 93
2013 103
2014 136
2015 122
2016 131
2017 142
2018 143
2019 71
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

2,231 results
Results by year
Filters applied: . Clear all
Page 1
Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer.
Öhlund D, et al. J Exp Med 2017. PMID 28232471 Free PMC article.
Pancreatic stellate cells (PSCs) differentiate into cancer-associated fibroblasts (CAFs) that produce desmoplastic stroma, thereby modulating disease progression and therapeutic response in pancreatic ductal adenocarcinoma (PDA). ...
Pancreatic stellate cells (PSCs) differentiate into cancer-associated fibroblasts (CAFs) that produce desmoplastic stroma, thereby mo
Immunotherapy and Prevention of Pancreatic Cancer.
Morrison AH, et al. Trends Cancer 2018 - Review. PMID 29860986 Free PMC article.
Pancreatic cancer is the third-leading cause of cancer mortality in the USA, recently surpassing breast cancer. A key component of pancreatic cancer's lethality is its acquired immune privilege, which is driven by an immunosuppressive microenvironment, poor T cell infiltration, and a low mutational burden. ...In this Review article, we discuss promising immunotherapies currently under investigation in pancreatic cancer and provide a roadmap for the development of prevention vaccines for this and other cancers....
Pancreatic cancer is the third-leading cause of cancer mortality in the USA, recently surpassing breast cancer. A key component of
Immunotherapy for pancreatic cancer: present and future.
Aroldi F and Zaniboni A. Immunotherapy 2017 - Review. PMID 28595517
Despite the identification of some efficient drugs for the treatment of metastatic pancreatic cancer, this tumor remains one of the most lethal cancers and is characterized by a strong resistance to therapies. ...Therefore, the immune system has been hypothesized to play an important role in pancreatic cancer. Thus, therapies acting on innate or adaptive immunity are being investigated. ...
Despite the identification of some efficient drugs for the treatment of metastatic pancreatic cancer, this tumor remains one of the m …
Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer.
Macherla S, et al. Int J Mol Sci 2018 - Review. PMID 30405053 Free PMC article.
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers associated with high morbidity and mortality. Based on available data, it's obvious that ICB has limited success in PDACs, which can be explained by the low immunogenicity and immunosuppressive tumor microenvironment of these tumors. ...
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers associated with high morbidity and mortality. Based on
Current progress in immunotherapy for pancreatic cancer.
Foley K, et al. Cancer Lett 2016 - Review. PMID 26723878 Free PMC article.
Pancreatic cancer remains one of the most lethal cancers with few treatment options. Immune-based strategies to treat pancreatic cancer, such as immune checkpoint inhibitors, therapeutic vaccines, and combination immunotherapies, are showing promise where other approaches have failed. ...In pancreatic cancer, early studies suggest that vaccines can induce T cells that have the potential to recognize and kill pancreatic cancer cells, but the tumor microenvironment inhibits effective T cell trafficking and function. ...
Pancreatic cancer remains one of the most lethal cancers with few treatment options. Immune-based strategies to treat pancreatic
Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival
Özdemir BC, et al. Cancer Cell 2014. PMID 24856586 Free PMC article.
Pancreatic ductal adenocarcinoma (PDAC) is associated with marked fibrosis and stromal myofibroblasts, but their functional contribution remains unknown. Transgenic mice with the ability to delete αSMA(+) myofibroblasts in pancreatic cancer were generated. Depletion starting at either noninvasive precursor (pancreatic intraepithelial neoplasia) or the PDAC stage led to invasive, undifferentiated tumors with enhanced hypoxia, epithelial-to-mesenchymal transition, and cancer stem cells, with diminished animal survival. ...
Pancreatic ductal adenocarcinoma (PDAC) is associated with marked fibrosis and stromal myofibroblasts, but their functional contribut
Immunotherapy for Pancreatic Cancer: More Than Just a Gut Feeling.
Riquelme E, et al. Cancer Discov 2018. PMID 29610286 Free article.
<b/> Development of pancreatic cancer in spontaneous murine models is associated with enrichment of specific strains of gut and intratumoral bacteria that induce a tolerogenic immunosuppressive microenvironment favoring cancer progression and resistance to immunotherapies. ...
Development of pancreatic cancer in spontaneous murine models is associated with enrichment of specific strains of gut and …
Pancreatic cancer, inflammation, and microbiome.
Zambirinis CP, et al. Cancer J 2014 - Review. PMID 24855007 Free PMC article.
Inflammatory conditions such as pancreatitis represent a well-known risk factor for pancreatic cancer development. Yet only in the past 2 decades has pancreatic cancer been recognized as an inflammation-driven cancer, and the precise mechanisms underlying the pathogenic role of inflammation are beginning to be explored in detail. ...The elucidation of the interplay between inflammation and microbiome in the context of pancreatic carcinogenesis will provide novel targets for intervention to prevent and treat pancreatic cancer more efficiently. ...
Inflammatory conditions such as pancreatitis represent a well-known risk factor for pancreatic cancer development. Yet only in the pa …
The Hippo Signaling Pathway in Pancreatic Cancer.
Ansari D, et al. Anticancer Res 2019 - Review. PMID 31262852
Pancreatic cancer is associated with an abundant stromal reaction leading to tumor growth and immune escape. It has been found that YAP and TAZ modulate behavior of pancreatic stellate cells and recruitment of tumor-associated macrophages and myeloid-derived suppressor cells. Moreover, YAP and TAZ are associated with chemoresistance and poor prognosis in pancreatic cancer. This review dissects the role of Hippo signaling in pancreatic cancer, focusing on molecular mechanisms and prospects for future intervention....
Pancreatic cancer is associated with an abundant stromal reaction leading to tumor growth and immune escape. It has been found that Y
Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer.
Feig C, et al. Proc Natl Acad Sci U S A 2013. PMID 24277834 Free PMC article.
An autochthonous model of pancreatic ductal adenocarcinoma (PDA) permitted the analysis of why immunotherapy is ineffective in this human disease. ...
An autochthonous model of pancreatic ductal adenocarcinoma (PDA) permitted the analysis of why immunotherapy is ineffective in this h …
2,231 results
Jump to page
Feedback